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EDITORIAL
Interleukin-1 as a mediator of tubulointerstitial fibrosis
Renal trainees often appear eager to learn the his- or AT1 receptor blockade attenuates the renal lesion, as
tologic features of the many categories of glomerulo- does AT1 receptor gene knockout, supporting a key role
nephritis, yet do not seem to share the same degree for angiotensin II, perhaps by its ability to stimulate tu-
of enthusiasm regarding the topic of tubulointerstitial bular NF-B and TGF-1 production [3]. Among an
fibrosis (TIF). It is no wonder. The histologic appearance extensive list of other candidate mediators, the role of
of the tubulointerstitium in most progressive kidney dis- nitric oxide (NO) has received attention. In ureteral ob-
eases of glomerular and non-glomerular origin is highly struction, arginine supplementation (which increases re-
predictable, often generating only passing commentary nal NO production) improves TIF [4]. The mechanism
at renal biopsy conferences, where the focus tends to be is unclear, but it could involve an NO-mediated reduc-
on the distinct glomerular changes. With progressive tion in oxidative stress pathways in the interstitium.
TIF, increased tubular cell apoptosis occurs, resulting in In this issue of Kidney International, Vesey et al add to
tubular atrophy and expansion of the interstitial volume, the body of evidence that the proinflammatory cytokine
with loss of capillaries. The interstitium accumulates interleukin-1 (IL-1) is a critical mediator of TIF [5].
matrix proteins such as collagens I, III, IV, V, VII, fi- Previous studies indicate that tubulointerstitial IL-1
bronectin, and laminin. Accompanying this lesion is a expression increases in the rat remnant kidney [6], and
fascinating, but deadly, phenomenon—the appearance IL-1 antagonists inhibit renal fibrosis in experimental
of interstitial myofibroblasts, identified by expression of models [7]. The source of IL-1 appears to be infiltrating
the mesenchymal marker -smooth muscle cell actin macrophages, which are present in the tubulointerstitium
(-SMA). Myofibroblasts are highly fibrogenic, contrac- in chronic kidney disease and which accumulate at least
tile, and may originate from “transdifferentiation” of partly because of the enhanced tubular and interstitial
tubular cells, which lose apical basal polarity and tight cell expression of chemokines such as monocyte chemo-
junctions. These cells may elongate, detach from the base- attractant protein-1 [6].
ment membrane, and migrate into the interstitium [1]. Using human proximal tubule epithelial cells in cul-
Certainly, TIF is reliably found in end-stage kidney ture, Vesey et al show that IL-1 caused a dose- and time-
disease, but we should make no mistake about it. Eluci- dependent increase in production of the matrix protein
dation of the mechanisms for this lesion is critical to fibronectin, associated with increased secretion of TGF-1.
development of effective therapies aimed at halting pro- The effects were not subtle. IL-1 at concentrations in
gressive kidney failure. It is well-established that in many the range of those associated with macrophage release
glomerulonephritides, histologic grading of TIF corre- in vivo (1 ng/mL) caused a fourfold increase in fibronec-
lates more closely with the decline in renal function than tin, and a twofold elevation of TGF-1. Of significance,
the grading of glomerulosclerosis [2]. Accordingly, TIF a TGF-1 neutralizing antibody blocked the effect of
is the final common pathway to end-stage kidney disease, IL-1 on fibronectin secretion and reversed inhibitory ef-
and contributes to loss of function by several mecha- fects on DNA synthesis. This suggests a pathway whereby
nisms, including increased backleak of filtrate through IL-1 stimulates human tubular cells to secrete TGF-1,
denuded tubular basement membranes and decreased which then acts in an autocrine loop to stimulate matrix
filtration associated with atubular glomeruli. How does protein production and suppress cell proliferation.
TIF happen? A second important finding is that IL-1 caused mor-
Increased tubular production of the cytokine trans- phologic changes of myofibroblastic transdifferentiation,
forming growth factor-1 (TGF-1) contributes impor- associated with increased expression of -SMA. Since this
tantly to TIF by stimulating deposition of matrix proteins is a cell culture study, it is difficult to exclude the possibil-
and inhibiting degradation, a process involving activation ity that IL-1-induced proximal tubule cell injury led to
of the transcription factor nuclear factor-B (NF-B). some overgrowth of fibroblasts in the culture dish, as
In unilateral ureteral obstruction, a well-studied model Vesey et al acknowledge [5]. Nonetheless, the results
of TIF, angiotensin-converting enzyme (ACE) inhibition are intriguing in the context of the pathogenesis of TIF.
In addition, other questions are raised, including whether
TGF-1 production contributes to the transdifferentia-Key words: collagens, myofibroblasts, laminin, fibronectin, glomerulo-
nephritis, apoptosis, basement membranes. tion process induced by IL-1, a model proposed by Fan
et al in studies involving cultured rat tubular cells [8]. 2002 by the International Society of Nephrology
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Finally, Vesey et al address the role of NO in this improve and expand our stock of therapies to combat
progression.process. As expected, IL-1 increased proximal tubule
expression of NO synthase-2, and stimulated levels of
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synthesis, at least in proximal tubule. And the jury is
still out on the role of NO. For instance, it remains REFERENCES
to be determined if NO is involved in myofibroblast
1. Ng Y-Y, Huang T-P, Yang W-C, et al: Tubular epithelial-myofi-transdifferentiation, since these authors did not report broblast transdifferentiation in progressive tubulointerstitial fibrosis
the effects of NO inhibition on cell morphology or in 5/6 nephrectomized rats. Kidney Int 54:864–876, 1998
2. Nath KA: Tubulointerstitial changes as a major determinant in the-SMA expression. Indeed, recent studies show that cy-
progression of renal damage. Am J Kidney Dis 20:1–17, 1992tokine-induced loss of cell adhesion in human proximal 3. Satoh M, Kashihara N, Yamasaki Y, et al: Renal interstitial fibrosis
tubule cells is mediated by autocrine effects of NO [9], is reduced in angiotensin II type 1A receptor-deficient mice. J Am
Soc Nephrol 12:317–325, 2001suggesting that the overall effect of NO may be deleteri-
4. Morrissey JJ, Ishidoya S, McCracken R, Klahr S: Nitric oxideous at the tubular cell level. generation ameliorates the tubulointerstitial fibrosis of obstructive
Vesey et al have provided insight into the puzzle of nephropathy. J Am Soc Nephrol 7:2202–2212, 1996
5. Vesey DA, Cheung CWY, Cuttle L, et al: Interleukin-1 inducesTIF, by suggesting a unifying pathway whereby inter-
human proximal tubule cell injury, -smooth muscle actin expres-stitial macrophages release IL-1, which then inhibits sion and fibronectin production. Kidney Int 62:31–40, 2002
tubule cell growth, but stimulates the cells to transdif- 6. Taal MW, Zandi-Nejad K, Weening B, et al: Proinflammatory
gene expression and macrophage recruitment in the rat remnantferentiate and produce matrix proteins via a TGF-1
kidney. Kidney Int 58:1664–1676, 2000autocrine loop. What happens next? In addition to the 7. Lan HY, Nikolic-Paterson DJ, Mu W, et al: Interleukin-1 receptor
need for more studies, in vitro and in vivo, on the func- antagonist halts the progression of established crescentic glomerulo-
nephritis in the rat. Kidney Int 47:1303–1309, 1995tion and regulation of NO and TGF-1, and on myofi-
8. Fan J-M, Huang X-R, Ng Y-Y, et al: Interleukin-1 induces tubularbroblast transdifferentiation, the time appears ripe to epithelial-myofibroblast transdifferentiation through a transforming
consider a clinical trial of IL-1 receptor antagonists in growth factor-1-dependent mechanism in vitro. Am J Kidney Dis
37:820–831, 2001humans with chronic kidney disease. After all, while TIF
9. Glynne PA, Picot J, Evans TJ: Coexpressed nitric oxide synthaserepresents a final common pathway, it is evident that and apical 1 integrins influence tubule cell adhesion after cytokine-
induced injury. J Am Soc Nephrol 12:2370–2383, 2001there are several mediators, and there is a clear need to
